Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation

PLoS Medicine

Volumn 11, Issue 12, 2014, Pages

  Kim, Ji Hoon ^a,b   Sohn, Bo Hwa ^a   Lee, Hyun Sung ^a   Kim, Sang Bae ^a   Yoo, Jeong Eun ^c   Park, Yun Yong ^d   Jeong, Woojin ^e   Lee, Sung Sook ^f   Park, Eun Sung ^c   Kaseb, Ahmed ^a   Kim, Baek Hui ^b   Kim, Wan Bae ^b   Yeon, Jong Eun ^b   Byun, Kwan Soo ^b   Chu, In Sun ^g   Kim, Sung Soo ^h   Wang, Xin Wei ⁱ   Thorgeirsson, Snorri S ⁱ   Luk, John M ^j   Kang, Koo Jeong ^k   Heo, Jeonghoon ^l   Park, Young Nyun ^c   Lee, Ju Seog ^a,h   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Internal Medicine University College of Medicine ^*  (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Ewha Womans University   (South Korea)

^f Inje University   (South Korea)

^g Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^h Kyung Hee University Hospital   (South Korea)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k Keimyung University School of Medicine   (South Korea)

^l Kosin University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 RECEPTOR; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; FEMALE; GENE EXPRESSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LIVER RESECTION; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR INVASION; GENETICS; LIVER TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84920973424     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001770     Document Type: Article

References (55)

1. International Agency for Research on Cancer (2013) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon (France): International Agency for Research on Cancer.
2. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB, (2004) Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127: 1372–1380.
3. El Serag HB, Mason AC, (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745–750.
4. El Serag HB, (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27–S34.
5. Bruix J, Llovet JM, (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519–524.
6. Bruix J, Sherman M, (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208–1236.
7. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200–207.
8. Llovet JM, Fuster J, Bruix J, (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434–1440.
9. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, et al. (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500–507.
10. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436–444.
11. Bosch FX, Ribes J, Cleries R, Diaz M, (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191–211.
12. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576.
13. Sun B, Karin M, (2013) Inflammation and liver tumorigenesis. Front Med 7: 242–254.
14. Dvorak HF, (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650–1659.
15. Haddow A, (1972) Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv Cancer Res 16: 181–234.
16. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, et al. (2003) Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361: 923–929.
17. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–676.
18. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, et al. (2008) Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 14: 2056–2064.
19. Ye QH, Qin LX, Forgues M, He P, Kim JW, et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416–423.
20. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995–2004.
21. Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99–111.
22. Wang SM, Ooi LL, Hui KM, (2007) Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13: 6275–6283.
23. Wang SM, Ooi LL, Hui KM, (2011) Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 17: 6040–6051.
24. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, et al. (2010) microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 6: 402.
25. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, et al. (2011) Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142: 957–966.
26. de Jonge J, Kurian S, Shaked A, Reddy KR, Hancock W, et al. (2009) Unique early gene expression patterns in human adult-to-adult living donor liver grafts compared to deceased donor grafts. Am J Transplant 9: 758–772.
27. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185–193.
28. Simon R, Lam A, Li M-C, Ngan M, Menenzes S, et al. (2007) Analysis of gene expression data using BRB-Array Tools. Cancer Inform 3: 11–17.
29. Wright GW, Simon RM, (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448–2455.
30. Radmacher MD, McShane LM, Simon R, (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505–511.
31. Tibshirani R, Hastie T, Narasimhan B, Chu G, (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567–6572.
32. Cox DR, (1972) Regression models with life tables. J R Stat Soc 34: 187–220.
33. Kramer A, Green J, Pollard J, JrTugendreich S, (2014) Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30: 523–530.
34. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, et al. (2011) Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55: 1443–1452.
35. Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, et al. (2006) Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 202: 275–283.
36. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, et al. (2004) Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 85: 36–41.
37. Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, et al. (1996) Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 111: 720–726.
38. Man K, Lo CM, Xiao JW, Ng KT, Sun BS, et al. (2008) The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 247: 1049–1057.
39. Shi JH, Huitfeldt HS, Suo ZH, Line PD, (2011) Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl 17: 866–874.
40. van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, et al. (2005) Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 42: 165–175.
41. van der Bilt JD, Kranenburg O, Borren A, van HR, Borel Rinkes IH, (2008) Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol 15: 1392–1398.
42. Man K, Ng KT, Lo CM, Ho JW, Sun BS, et al. (2007) Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases—activation of cell invasion and migration pathways. Liver Transpl 13: 1669–1677.
43. Wang H, Huang ZQ, Xia L, Feng Q, Erdjument-Bromage H, et al. (2001) Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293: 853–857.
44. Poser SW, Park DM, Androutsellis-Theotokis A, (2013) The STAT3-Ser/Hes3 signaling axis: an emerging regulator of endogenous regeneration and cancer growth. Front Physiol 4: 273.
45. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, et al. (2010) Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17: 286–297.
46. Yu H, Pardoll D, Jove R, (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798–809.
47. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121–124.
48. Radaeva S, Sun R, Pan HN, Hong F, Gao B, (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332–1342.
49. Saxena NK, Sharma D, Ding X, Lin S, Marra F, et al. (2007) Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497–2507.
50. Liu J, Sato C, Cerletti M, Wagers A, (2010) Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 92: 367–409.
51. Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, et al. (2014) RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Mol Oncol 8: 1043–1053.
52. Ding X, Wang K, Wang H, Zhang G, Liu Y, et al. (2012) High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg 16: 828–836.
53. Yang SF, Yeh YT, Wang SN, Hung SC, Chen WT, et al. (2008) SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. Pathology 40: 558–563.
54. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS, (2011) Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 10: 9–15.
55. Sansone P, Bromberg J, (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30: 1005–1014.